Navigation Links
Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column

T.J. Higley and Roy Eksteen, Tosoh Bioscience LLC, Montgomeryville, Pennsylvania and Scott Lauder, Lexigen Pharmaceuticals, Lexington, Massachusetts

During method development, many variables are examined to ensure method robustness. Factors such as elution profile, peak shape, and recovery are required to be consistent by GMP/GLP protocols. During a recent method re-qualification at Lexigen Pharmaceuticals, several variables were investigated to eliminate non-specific binding and increase the robustness of an established antibody separation method. Previous protocol required an unacceptable two-week "break-in" period to equilibrate the column with the mobile phase. Reduction of non-specific binding of proteins to SEC stationary phases can be achieved by exploring variables that affect either the ionic strength or hydrophobicity of the mobile phase. Typically, changes in mobile phase composition, such as buffer type and pH, salt concentration, the addition of organic modifiers, as well as the evaluation of competitive columns are the usual strategies to correcting non-specific adsorption. In this case, these options did not result in an improvement. Thus, an alternative approach to increase the chaotropic nature of the mobile phase was investigated. Concurrently, the buffer concentration was reduced to a minimum buffering capacity and the modifying salt was changed to NaClO4. A drastic improvement on the performance of the method was evident.

Experimental Conditions:
Gel filtration was performed with a 4.6mmID x 30cm TSKgel Super SW3000 column packed with 4m particles containing 250 pores. The original run ning buffer consisted of 0.1M NaH2PO4 (pH 6.0) to which was added 15% acetonitrile and 0.2M NaCl. In the redesigned buffer system, NaCl was replaced by NaClO4 and the phosphate buffer concentration was reduced to 0.05M. Initially, the concentration of sodium perchlorate investigated was 0.2M, however, best results were obtained at 0.4M. The flow rate of 0.35mL/min was left unchanged. Note that recent work has shown that acetonitrile can be omitted from the mobile phase without affecting separation quality or method robustness.

As shown in Figure 1 , excessive peak tailing of "fusion protein 1" is evident with the use of 0.2M NaCl. Additionally, the expected protein dimer and trimer aggregates are not visible in the chromatogram. By switching from 0.2M sodium chloride to 0.2M of the more chaotropic sodium perchlorate salt, together with a two-fold reduction in the buffer concentration, less peak tailing and distinct peaks for the dimer and trimer species of MAb1 resulted. Doubling the perchlorate concentration to 0.4M provided further improvement in the peak shape of fusion protein 1 and associated aggregate species. Additionally, the re-development increased the methods' robustness allowing for a substantial decrease in column "break-in" time from two weeks to 4 days as well as better peak area reproducibility and linearity of both monomer and aggregate species.

As a precaution, a more rigorous cleaning protocol consisting of flushing the system with DI water was implemented during periods of instrument inactivity. Although perchlorate is slightly less corrosive to stainless steel components relative to chloride, it is considered more aggressive to chemically bonded stationary phases.

The selection of sodium perchlorate as a mobile phase component substantially improved the analysis and quantification of an experimental monoclonal antibody and its aggregates by SEC, thus providing the required level of method robustness.

More Infomation
TSKgel SuperSW3000



Page: All 1 2 3

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
5. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
6. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
7. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
8. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
9. Two-dimensional Optimization of a Semi-nested PCR for Detecting Listeria monocytogenes
10. PCR Optimization
11. PCR Optimization Kit
Post Your Comments:

(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):